Cell and Tissue Research

, Volume 339, Issue 1, pp 155–165 | Cite as

Unexpected matrix diseases and novel therapeutic strategies



Within the framework of a broad definition of the extracellular matrix (ECM), this review discusses three genetic disorders in which major pathogenetic features have been traced back to alterations in the levels/activities of matrix components. In each case, disease-associated alterations are found both intra- and extracellularly. The nature of the ECM involvement is surprising, offers an exciting therapeutic opportunity, and deepens our understanding of ECM-cell interactions. The first of these disorders, cherubism, is a case of inflammatory bone loss in the jaws of children for reasons that are surprisingly systemic in nature, considering the local nature of the disease. The primary defect involves an intracellular signaling molecule, but a major pathogenetic component and therapeutic target of the disease is the extracellular cytokine tumor necrosis factor alpha. The second disorder, Knobloch syndrome, is caused by recessive mutations in collagen XVIII. Although this protein has been classified as belonging to a group of structural macromolecules, the consequence of the mutations is impairment of cellular metabolism. The third disorder, infantile hemangioma, is a common tumor of capillary endothelial cells in infancy. The tumor appears within a few days/weeks after birth, grows rapidly over several months, and regresses over several years. The proliferative phase is the result of constitutively high levels of vascular endothelial cell growth factor (VEGF)-dependent signaling through VEGF receptor 2 (VEGFR2), but recent studies have led to the surprising conclusion that abnormalities in a cell-surface receptor complex controlling expression of the VEGF decoy receptor VEGFR1 is the underlying cause.


Extracellular matrix Cherubism Infantile hemangioma Knobloch syndrome 


  1. Aliprantis AO, Ueki Y, Sulyanto R, Park A, Sigrist KS, Sharma SM, Ostrowski MC, Olsen BR, Glimcher LH (2008) NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism. J Clin Invest 118:3775–3789CrossRefPubMedGoogle Scholar
  2. Angelin A, Tiepolo T, Sabatelli P, Grumati P, Bergamin N, Golfieri C, Mattioli E, Gualandi F, Ferlini A, Merlini L, Maraldi NM, Bonaldo P, Bernardi P (2007) Mitochondrial dysfunction in the pathogenesis of Ullrich congenital muscular dystrophy and prospective therapy with cyclosporins. Proc Natl Acad Sci USA 104:991–996CrossRefPubMedGoogle Scholar
  3. Barnes CM, Huang S, Kaipainen A, Sanoudou D, Chen EJ, Eichler GS, Guo Y, Yu Y, Ingber DE, Mulliken JB, Beggs AH, Folkman J, Fishman SJ (2005) Evidence by molecular profiling for a placental origin of infantile hemangioma. Proc Natl Acad Sci USA 102:19097–19102CrossRefPubMedGoogle Scholar
  4. Bellucci C, Lilli C, Baroni T, Parnetti L, Sorbi S, Emiliani C, Lumare E, Calabresi P, Balloni S, Bodo M (2007) Differences in extracellular matrix production and basic fibroblast growth factor response in skin fibroblasts from sporadic and familial Alzheimer’s disease. Mol Med 13:542–550CrossRefPubMedGoogle Scholar
  5. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP (1997) A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385:729–733CrossRefPubMedGoogle Scholar
  6. Blei F, Walter J, Orlow SJ, Marchuk DA (1998) Familial segregation of hemangiomas and vascular malformations as an autosomal dominant trait. Arch Dermatol 134:718–722 [erratum in Arch Dermatol 134:1425]CrossRefPubMedGoogle Scholar
  7. Boon LM, MacDonald DM, Mulliken JB (1999) Complications of systemic corticosteroid therapy for problematic hemangioma. Plast Reconstr Surg 104:1616–1623CrossRefPubMedGoogle Scholar
  8. Boye E, Olsen BR (2009) Signaling mechanisms in infantile hemangioma. Curr Opin Hematol 16:202–208CrossRefPubMedGoogle Scholar
  9. Boye E, Yu Y, Paranya G, Mulliken JB, Olsen BR, Bischoff J (2001) Clonality and altered behavior of endothelial cells from hemangiomas. J Clin Invest 107:745–752CrossRefPubMedGoogle Scholar
  10. Bradley JR (2008) TNF-mediated inflammatory disease. J Pathol 214:149–160CrossRefPubMedGoogle Scholar
  11. Bradley KA, Mogridge J, Mourez M, Collier RJ, Young JA (2001) Identification of the cellular receptor for anthrax toxin. Nature 414:225–229CrossRefPubMedGoogle Scholar
  12. Brennan FM, McInnes IB (2008) Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 118:3537–3545CrossRefPubMedGoogle Scholar
  13. Chen R, Gao B, Huang C, Olsen B, Rotundo RF, Blumenstock F, Saba TM (2000) Transglutaminase-mediated fibronectin multimerization in lung endothelial matrix in response to TNF-alpha. Am J Physiol Lung Cell Mol Physiol 279:L161–L174PubMedGoogle Scholar
  14. Chen CC, Young JL, Monzon RI, Chen N, Todorovic V, Lau LF (2007) Cytotoxicity of TNFalpha is regulated by integrin-mediated matrix signaling. EMBO J 26:1257–1267CrossRefPubMedGoogle Scholar
  15. Cheng JS, Dubal DB, Kim DH, Legleiter J, Cheng IH, Yu GQ, Tesseur I, Wyss-Coray T, Bonaldo P, Mucke L (2009) Collagen VI protects neurons against Abeta toxicity. Nat Neurosci 12:119–121CrossRefPubMedGoogle Scholar
  16. Chiller KG, Passaro D, Frieden IJ (2002) Hemangiomas of infancy: clinical characteristics, morphologic subtypes, and their relationship to race, ethnicity, and sex. Arch Dermatol 138:1567–1576CrossRefPubMedGoogle Scholar
  17. Cicchetti P, Mayer BJ, Thiel G, Baltimore D (1992) Identification of a protein that binds to the SH3 region of Abl and is similar to Bcr and GAP-rho. Science 257:803–806CrossRefPubMedGoogle Scholar
  18. Clark IM, Swingler TE, Sampieri CL, Edwards DR (2008) The regulation of matrix metalloproteinases and their inhibitors. Int J Biochem Cell Biol 40:1362–1378CrossRefPubMedGoogle Scholar
  19. Deckert M, Tartare-Deckert S, Couture C, Mustelin T, Altman A (1996) Functional and physical interactions of Syk family kinases with the Vav proto-oncogene product. Immunity 5:591–604CrossRefPubMedGoogle Scholar
  20. Deckert M, Tartare-Deckert S, Hernandez J, Rottapel R, Altman A (1998) Adaptor function for the Syk kinases-interacting protein 3BP2 in IL-2 gene activation. Immunity 9:595–605CrossRefPubMedGoogle Scholar
  21. Dong S, Cole GJ, Halfter W (2003) Expression of collagen XVIII and localization of its glycosaminoglycan attachment sites. J Biol Chem 278:1700–1707CrossRefPubMedGoogle Scholar
  22. Duh EJ, Yao YG, Dagli M, Goldberg MF (2004) Persistence of fetal vasculature in a patient with Knobloch syndrome: potential role for endostatin in fetal vascular remodeling of the eye. Ophthalmology 111:1885–1888PubMedGoogle Scholar
  23. Enjolras O, Breviere GM, Roger G, Tovi M, Pellegrino B, Varotti E, Soupre V, Picard A, Leverger G (2004) Vincristine treatment for function- and life-threatening infantile hemangioma. Arch Pediatr 11:99–107CrossRefPubMedGoogle Scholar
  24. Ezekowitz RA, Mulliken JB, Folkman J (1992) Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 326:1456–1463PubMedGoogle Scholar
  25. Fanjul-Fernandez M, Folgueras AR, Cabrera S, Lopez-Otin C (2009) Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models. Biochim Biophys Acta (in press)Google Scholar
  26. Fawcett SL, Grant I, Hall PN, Kelsall AW, Nicholson JC (2004) Vincristine as a treatment for a large haemangioma threatening vital functions. Br J Plast Surg 57:168–171CrossRefPubMedGoogle Scholar
  27. Foucault I, Liu YC, Bernard A, Deckert M (2003) The chaperone protein 14–3-3 interacts with 3BP2/SH3BP2 and regulates its adapter function. J Biol Chem 278:7146–7153CrossRefPubMedGoogle Scholar
  28. Foucault I, Le Bras S, Charvet C, Moon C, Altman A, Deckert M (2005) The adaptor protein 3BP2 associates with VAV guanine nucleotide exchange factors to regulate NFAT activation by the B-cell antigen receptor. Blood 105:1106–1113CrossRefPubMedGoogle Scholar
  29. Fukai N, Eklund L, Marneros AG, Oh SP, Keene DR, Tamarkin L, Li E, Pihlajaniemi T, Olsen BR (2002) Lack of collagen XVIII/endostatin results in eye abnormalities. EMBO J 21:1535–1544CrossRefPubMedGoogle Scholar
  30. Gao B, Curtis TM, Blumenstock FA, Minnear FL, Saba TM (2000) Increased recycling of (alpha)5(beta)1 integrins by lung endothelial cells in response to tumor necrosis factor. J Cell Sci 113:247–257PubMedGoogle Scholar
  31. Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, Myers L, Klein EC, Liu G, Calvi C, Podowski M, Neptune ER, Halushka MK, Bedja D, Gabrielson K, Rifkin DB, Carta L, Ramirez F, Huso DL, Dietz HC (2006) Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science 312:117–121CrossRefPubMedGoogle Scholar
  32. Haggstrom AN, Drolet BA, Baselga E, Chamlin SL, Garzon MC, Horii KA, Lucky AW, Mancini AJ, Metry DW, Newell B, Nopper AJ, Frieden IJ (2007) Prospective study of infantile hemangiomas: demographic, prenatal, and perinatal characteristics. J Pediatr 150:291–294CrossRefPubMedGoogle Scholar
  33. Halfter W, Dong S, Schurer B, Cole GJ (1998) Collagen XVIII is a basement membrane heparan sulfate proteoglycan. J Biol Chem 273:25404–25412CrossRefPubMedGoogle Scholar
  34. Hidano A, Nakajima S (1972) Earliest features of the strawberry mark in the newborn. Br J Dermatol 87:138–144CrossRefPubMedGoogle Scholar
  35. Hotchkiss KA, Basile CM, Spring SC, Bonuccelli G, Lisanti MP, Terman BI (2005) TEM8 expression stimulates endothelial cell adhesion and migration by regulating cell-matrix interactions on collagen. Exp Cell Res 305:133–144CrossRefPubMedGoogle Scholar
  36. Imai Y, Kanno K, Moriya T, Kayano S, Seino H, Matsubara Y, Yamada A (2003) A missense mutation in the SH3BP2 gene on chromosome 4p16.3 found in a case of nonfamilial cherubism. Cleft Palate Craniofac J 40:632–638CrossRefPubMedGoogle Scholar
  37. Jinnin M, Medici D, Park L, Limaye N, Liu Y, Boscolo E, Bischoff J, Vikkula M, Boye E, Olsen BR (2008) Suppressed NFAT-dependent VEGFR1 expression and constitutive VEGFR2 signaling in infantile hemangioma. Nat Med 14:1236–1246CrossRefPubMedGoogle Scholar
  38. Jones WA (1933) Familial multilocular cystic disease of the jaws. Am J Cancer 17:946–950Google Scholar
  39. Knobloch WH, Layer JM (1972) Clefting syndromes associated with retinal detachment. Am J Ophthalmol 73:517–530PubMedGoogle Scholar
  40. Kriegler M, Perez C, DeFay K, Albert I, Lu SD (1988) A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell 53:45–53CrossRefPubMedGoogle Scholar
  41. Leaute-Labreze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taieb A (2008) Propranolol for severe hemangiomas of infancy. N Engl J Med 358:2649–2651CrossRefPubMedGoogle Scholar
  42. Li CY, Yu SF (2006) A novel mutation in the SH3BP2 gene causes cherubism: case report. BMC Med Genet 7:84CrossRefPubMedGoogle Scholar
  43. Lietman SA, Kalinchinko N, Deng X, Kohanski R, Levine MA (2006) Identification of a novel mutation of SH3BP2 in cherubism and demonstration that SH3BP2 mutations lead to increased NFAT activation. Hum Mutat 27:717–718CrossRefPubMedGoogle Scholar
  44. Limaye N, Wouters V, Uebelhoer M, Tuominen M, Wirkkala R, Mulliken JB, Eklund L, Boon LM, Vikkula M (2009) Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations. Nat Genet 41:118–124CrossRefPubMedGoogle Scholar
  45. Lo B, Faiyaz-Ul-Haque M, Kennedy S, Aviv R, Tsui LC, Teebi AS (2003) Novel mutation in the gene encoding c-Abl-binding protein SH3BP2 causes cherubism. Am J Med Genet 121A:37–40CrossRefPubMedGoogle Scholar
  46. Mangion J, Rahman N, Edkins S, Barfoot R, Nguyen T, Sigurdsson A, Townend JV, Fitzpatrick DR, Flanagan AM, Stratton MR (1999) The gene for cherubism maps to chromosome 4p16.3. Am J Hum Genet 65:151–157CrossRefPubMedGoogle Scholar
  47. Marneros AG, Olsen BR (2003) Age-dependent iris abnormalities in collagen XVIII/endostatin deficient mice with similarities to human pigment dispersion syndrome. IOVS 44:2367–2372Google Scholar
  48. Marneros AG, Keene DR, Hansen U, Fukai N, Moulton K, Goletz PL, Moiseyev G, Pawlyk BS, Halfter W, Dong S, Shibata M, Li T, Crouch RK, Bruckner P, Olsen BR (2004) Collagen XVIII/endostatin is essential for vision and retinal pigment epithelial function. EMBO J 23:89–99CrossRefPubMedGoogle Scholar
  49. Marneros AG, She H, Zambarakji H, Hashizume H, Connoly EJ, Kim I, Gragoudas ES, Miller JW, Olsen BR (2007) Endogenous endostatin inhibits choroidal neovascularization. FASEB J 21:3809–3818CrossRefPubMedGoogle Scholar
  50. Matt P, Schoenhoff F, Habashi J, Holm T, Van Erp C, Loch D, Carlson OD, Griswold BF, Fu Q, De Backer J, Loeys B, Huso DL, McDonnell NB, Van Eyk JE, Dietz HC (2009) Circulating transforming growth factor-beta in Marfan syndrome. Circulation 120:526–532CrossRefPubMedGoogle Scholar
  51. Merlini L, Angelin A, Tiepolo T, Braghetta P, Sabatelli P, Zamparelli A, Ferlini A, Maraldi NM, Bonaldo P, Bernardi P (2008) Cyclosporin A corrects mitochondrial dysfunction and muscle apoptosis in patients with collagen VI myopathies. Proc Natl Acad Sci USA 105:5225–5229CrossRefPubMedGoogle Scholar
  52. Mulliken JB, Glowacki J (1982) Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg 69:412–422PubMedCrossRefGoogle Scholar
  53. Muragaki Y, Timmons S, Griffith CM, Oh SP, Fadel B, Quertermous T, Olsen BR (1995) Mouse Col18a1 is expressed in a tissue-specific manner as three alternative variants and is localized in basement membrane zones. Proc Natl Acad Sci USA 92:8763–8767CrossRefPubMedGoogle Scholar
  54. Nanda A, Carson-Walter EB, Seaman S, Barber TD, Stampfl J, Singh S, Vogelstein B, Kinzler KW, St Croix B (2004) TEM8 interacts with the cleaved C5 domain of collagen alpha 3(VI). Cancer Res 64:817–820CrossRefPubMedGoogle Scholar
  55. North PE, Waner M, Mizeracki A, Mihm MC Jr (2000) GLUT1: a newly discovered immunohistochemical marker for juvenile hemangiomas. Hum Pathol 31:11–22CrossRefPubMedGoogle Scholar
  56. North PE, Waner M, Mizeracki A, Mrak RE, Nicholas R, Kincannon J, Suen JY, Mihm MC Jr (2001) A unique microvascular phenotype shared by juvenile hemangiomas and human placenta. Arch Dermatol 137:559–570PubMedGoogle Scholar
  57. O’Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277–285CrossRefPubMedGoogle Scholar
  58. Olsen BR (2006) From the editor’s desk. Matrix Biol 25:269–270CrossRefGoogle Scholar
  59. Olsen BR (2007) From the editor’s desk. Matrix Biol 26:145CrossRefGoogle Scholar
  60. Osada Y, Hashimoto T, Nishimura A, Matsuo Y, Wakabayashi T, Iwatsubo T (2005) CLAC binds to amyloid beta peptides through the positively charged amino acid cluster within the collagenous domain 1 and inhibits formation of amyloid fibrils. J Biol Chem 280:8596–8605CrossRefPubMedGoogle Scholar
  61. Palma E, Tiepolo T, Angelin A, Sabatelli P, Maraldi NM, Basso E, Forte MA, Bernardi P, Bonaldo P (2009) Genetic ablation of cyclophilin D rescues mitochondrial defects and prevents muscle apoptosis in collagen VI myopathic mice. Hum Mol Genet 18:2024–2031CrossRefPubMedGoogle Scholar
  62. Read TA, Sorensen DR, Mahesparan R, Enger PO, Timpl R, Olsen BR, Hjelstuen MH, Haraldseth O, Bjerkvig R (2001) Local endostatin treatment of gliomas administered by microencapsulated producer cells. Nat Biotech 19:29–34CrossRefGoogle Scholar
  63. Ren R, Mayer BJ, Cicchetti P, Baltimore D (1993) Identification of a ten-amino acid proline-rich SH3 binding site. Science 259:1157–1161CrossRefPubMedGoogle Scholar
  64. Rehn M, Hintikka E, Pihlajaniemi T (1996) Characterization of the mouse gene for the alpha 1 chain of type XVIII collagen (Col18a1) reveals that the three variant N-terminal polypeptide forms are transcribed from two widely separated promoters. Genomics 32:436–446CrossRefPubMedGoogle Scholar
  65. Rodriguez C, Alcudia JF, Martinez-Gonzalez J, Raposo B, Navarro MA, Badimon L (2008) Lysyl oxidase (LOX) down-regulation by TNFalpha: a new mechanism underlying TNFalpha-induced endothelial dysfunction. Atherosclerosis 196:558–564CrossRefPubMedGoogle Scholar
  66. Rotundo RF, Curtis TM, Shah MD, Gao B, Mastrangelo A, LaFlamme SE, Saba TM (2002) TNF-alpha disruption of lung endothelial integrity: reduced integrin mediated adhesion to fibronectin. Am J Physiol Lung Cell Mol Physiol 282:L316–L329PubMedGoogle Scholar
  67. Saarela J, Rehn M, Oikarinen A, Autio-Harmainen H, Pihlajaniemi T (1998a) The short and long forms of type XVIII collagen show clear tissue specificities in their expression and location in basement membrane zones in humans. Am J Pathol 153:611–626PubMedGoogle Scholar
  68. Saarela J, Ylikarppa R, Rehn M, Purmonen S, Pihlajaniemi T (1998b) Complete primary structure of two variant forms of human type XVIII collagen and tissue-specific differences in the expression of the corresponding transcripts. Matrix Biol 16:319–328CrossRefPubMedGoogle Scholar
  69. Sertié AL, Quimby M, Moreira ES, Murray J, Zatz M, Antonarakis SE, Passos-Bueno MR (1996) A gene which causes severe ocular alterations and occipital encephalocele (Knobloch syndrome) is mapped to 21q22.3. Hum Mol Genet 5:843–847CrossRefPubMedGoogle Scholar
  70. Sertié AL, Sossi V, Camargo AA, Zatz M, Brahe C, Passos-Bueno MR (2000) Collagen XVIII, containing an endogenous inhibitor of angiogenesis and tumor growth, plays a critical role in the maintenance of retinal structure and in neural tube closure. Hum Mol Genet 9:2051–2058CrossRefPubMedGoogle Scholar
  71. Soderberg L, Dahlqvist C, Kakuyama H, Thyberg J, Ito A, Winblad B, Naslund J, Tjernberg LO (2005) Collagenous Alzheimer amyloid plaque component assembles amyloid fibrils into protease resistant aggregates. FEBS J 272:2231–2236CrossRefPubMedGoogle Scholar
  72. Suzuki O, Kague E, Bagatini K, Tu H, Heljasvaara R, Carvalhaes L, Gava E, Oliveira G de, Godoi P, Oliva G, Kitten G, Pihlajaniemi T, Passos-Bueno MR (2009) Novel pathogenic mutations and skin biopsy analysis in Knobloch syndrome. Mol Vis 15:801–809PubMedGoogle Scholar
  73. Tang P, Hung MC, Klostergaard J (1996) Human pro-tumor necrosis factor is a homotrimer. Biochemistry 35:8216–8225CrossRefPubMedGoogle Scholar
  74. Tiepolo T, Angelin A, Palma E, Sabatelli P, Merlini L, Nicolosi L, Finetti F, Braghetta P, Vuagniaux G, Dumont JM, Baldari CT, Bonaldo P, Bernardi P (2009) The cyclophilin inhibitor Debio 025 normalizes mitochondrial function, muscle apoptosis and ultrastructural defects in Col6a1(-/-) myopathic mice. Br J Pharmacol 157:1045–1052CrossRefPubMedGoogle Scholar
  75. Tiziani V, Reichenberger E, Buzzo CL, Niazi S, Fukai N, Stiller M, Peters H, Salzano FM, Raposo do Amaral CM, Olsen BR (1999) The gene for cherubism maps to chromosome 4p16. Am J Hum Genet 65:158–166CrossRefPubMedGoogle Scholar
  76. Tobinick EL, Gross H (2008) Rapid improvement in verbal fluency and aphasia following perispinal etanercept in Alzheimer’s disease. BMC Neurol 8:27CrossRefPubMedGoogle Scholar
  77. Ueki Y, Tiziani V, Santanna C, Fukai N, Maulik C, Garfinkle J, Ninomiya C, Raposo do Amaral CM, Peters H, Habal M, Rhee-Morris L, Doss JB, Kreiborg S, Olsen BR, Reichenberger E (2001) Mutations in the gene encoding c-Abl-binding protein SH3BP2 cause cherubism. Nat Genet 28:125–126CrossRefPubMedGoogle Scholar
  78. Ueki Y, Lin CY, Senoo M, Ebihara T, Agata N, Onji M, Saheki Y, Kawai T, Mukherjee PM, Reichenberger E, Olsen BR (2007) Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 “cherubism” mice. Cell 128:71–83CrossRefPubMedGoogle Scholar
  79. Vikkula M, Boon LM, Carraway K, Calvert JT, Diamonti AJ, Goumnerov B, Pasyk KA, Marchuk DA, Warman ML, Cantley LC, Mulliken JB, Olsen BR (1996) Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell 87:1181–1190CrossRefPubMedGoogle Scholar
  80. Werner E, Kowalczyk AP, Faundez V (2006) Anthrax toxin receptor 1/tumor endothelium marker 8 mediates cell spreading by coupling extracellular ligands to the actin cytoskeleton. J Biol Chem 281:23227–23236CrossRefPubMedGoogle Scholar
  81. Yamaguchi N, Anand-Apte B, Lee M, Sasaki T, Fukai N, Shapiro R, Que I, Lowik C, Timpl R, Olsen BR (1999) Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J 18:4414–4423CrossRefPubMedGoogle Scholar
  82. Ylikärppä R, Eklund L, Sormunen R, Utriainen A, Kontiola A, Määttä M, Muona A, Fukai N, Olsen BR, Pihlajaniemi T (2003) Lack of type XVIII collagen results in anterior ocular defects. FASEB J 17:2257–2259PubMedGoogle Scholar
  83. Zollino M, Di Stefano C, Zampino G, Mastroiacovo P, Wright TJ, Sorge G, Selicorni A, Tenconi R, Zappala A, Battaglia A, Di Rocco M, Palka G, Pallotta R, Altherr MR, Neri G (2000) Genotype-phenotype correlations and clinical diagnostic criteria in Wolf-Hirschhorn syndrome. Am J Med Genet 94:254–261CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  1. 1.Department of Developmental BiologyHarvard School of Dental MedicineBostonUSA

Personalised recommendations